Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
September, 2026
September 2026
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Wolfgang Miesbach: From Failed Intravitreal Trials to Real Benefit – Subretinal AAV8 Gene Therapy in Pediatric X-Linked Retinoschisis
Wolfgang Miesbach/LinkedIn
Jun 11, 2026, 16:37

Wolfgang Miesbach: From Failed Intravitreal Trials to Real Benefit – Subretinal AAV8 Gene Therapy in Pediatric X-Linked Retinoschisis

Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn about a recent article by Licong Liang, he and his colleagues co-authored, published in NEJM, adding:

“From failed intravitreal trials to real benefit:subretinal AAV8 gene therapy in pediatric X‑linked retinoschisis.

Yesterday’s NEJM study reports 1‑year data on subretinal AAV8‑based gene therapy (scAAV8‑hRS1) for X‑linked retinoschisis (XLRS) in children and adolescents, after earlier intravitreal AAV trials largely failed to show efficacy beyond isolated, transient schisis closure.

Patients

12 boys, 5–18 years, genetically confirmed RS1 variants

Single subretinal injection of scAAV8‑hRS1 (7.5×10¹⁰ or 1×10¹¹ vg) into the worse eye

Excluded: recent carbonic anhydrase inhibitors,AAV8‑neutralizing antibodies ≥1:1000

Vector and delivery
Self‑complementary AAV8 vector with codon‑optimized human RS1 cDNA (scAAV8‑hRS1)

Rhodopsin kinase promoter to photoreceptor‑selective expression

Subretinal route chosen to improve photoreceptor transduction versus intravitreal delivery, which in prior XLRS trials did not produce consistent functional or structural benefit

  • Safety at 52 weeks
  • 56 adverse events
  • No grade ≥3 events
  • No ocular inflammation reported
  • One macular hole in the treated eye at week 1 in a structurally fragile macula

Efficacy: clear signals.

Subretinal scAAV8‑hRS1 led to complete closure of schisis cavities in all treated eyes, substantial reduction in central retinal thickness, and a meaningful BCVA gain in the treated eye compared with the fellow eye at 1 year.

First pediatric XLRS gene therapy study to show consistent closure of schisis cavities in all treated eyes together with a meaningful BCVA gain versus the fellow eye.”

Title: Subretinal Gene Therapy for X-Linked Retinoschisis

Authors: Licong Liang, Kaiqin She, Chengda Ren, Rui Li, Meng Liao, Zhiyan Tao, Fanfei Liu, Jing Su, Ming Hu, Yiliu Yang, Xiaoyue Wang, Charlotte L. Zhang, Li Bao, Qin Chen, Kang Zhang, Yuquan Wei, Yang Yang, Fang Lu.

Wolfgang Miesbach: From Failed Intravitreal Trials to Real Benefit - Subretinal AAV8 Gene Therapy in Pediatric X-Linked Retinoschisis

Other posts featuring Wolfgang Miesbach on Hemostasis Today.

Charlotte L. Zhang Chengda Ren Fanfei Liu Fang Lu. Health Hematology Hemophilia Hemostasis Hemostasis News Hemostasis Today Jing Su Kaiqin She Kang Zhang Li Bao Licong Liang Medicine Meng Liao Ming Hu NEJM Qin Chen Rui Li stroke thrombosis Wolfgang Miesbach Xiaoyue Wang Yang Yang Yiliu Yang Yuquan Wei Zhiyan Tao
NewsFeed